![]()
- Credit Markets on Edge About When Fed Will Raise Rates
- Bove: Expect Goldman To Increase Dividend Meaningfully
- Bullish Sign for Gold: Central Banks Are Big Buyers
- Victoria's Secret Hopes to Rekindle Desire for Lingerie
- High Roller Sues Harrah's for Lost Millions
- Wall Street Jobs Slow to Return Despite Record Profits
- Big Shareholders Ask Goldman to Cut Bonuses: Report
- Buying an Expensive House? Government Can Help
- Review: What It's Like to Drive the New Chevy Volt
- How Stock Investors Can Play Holiday Travel
- Time Lapse World Series Is A Great Play
- Hirschhorn: Greed...or Fear
- My Top 10 Tech Toys for the Holidays
- iPhone a Better Gaming Platform Than Android?
- May Day For Dendreon
- 100% Mortgage Financing From USDA
- Holiday Tipping: Who And How Much
- Deep Discounts Should Make It a Very Tech-y Holiday
MOST SHARED
- Nielsen Ratings Coming to Video Games
- Confessions of a Black Friday Shopper
- The Week Ahead
- 'New Moon' Midnight Showings Earn Record $26.3 Million
- Oil Next Week
- Time Lapse World Series Is A Great Play
- Twilight, Inc., A Worldwide Craze
- Hershey Mulls $17 Billion Bid for Cadbury: Source
- Latest Bullish Sign for Gold: Central Banks Are Big Buyers
powered by digg
Experimental Swine Flu Drug Authorized by FDA
Topics:Pharmaceuticals
The Food and Drug Administration has given what's called Emergency Use Authorization for a new H1N1 flu drug.
That essentially gives BioCryst Pharmaceuticals regulatory special dispensation to sell its intravenous antiviral for use on certain, specified adult and pediatric cases of suspected or confirmed H1N1 that require hospitalization.
Peramivir is an antiviral, not a vaccine.
The CDC requested the FDA allow this special use of the drug, which is still considered experimental, but has been shown to be effective in clinical trials in fighting severe cases of the flu.
© 2009 CNBC.com
- Technology can make or break a fortune in the world of alternative energy.
- Many people are facing the holidays with substantially smaller incomes. Here’s how some are adapting.
- Jim Cramer is a proponent of stocks that pay healthy dividends, and here are his top five dividend plays.
- From salt, to lip balm to envelopes, it turns out that bacon flavoring can sell almost anything.
- The homebuyer's tax credit jacked sales for a while, but 2010 is looking weak. Now what?
- CNBC’s technology reporter Jim Goldman guides you through the best gadgets to buy this holiday season.
MORE FROM CNBC












